All In Biotech

Drug Trial Radar · NCT04961710

Extension Study of Hetrombopag in Severe Aplastic Anemia

Extension Study of Hetrombopag Olamine in Patients With Treatment-naive Severe Aplastic Anemia

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

157

Actual

Start

Sep 19, 2019

Primary completion

Nov 30, 2024

Study completion Dec 31, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 15 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, placebo-control, phase 3 study of hetrombopag in patients with treatment-naive severe aplastic anemia. All subjects who have completed or withdrawn from the HR-TPO-SAA-III study will voluntarily participate in this extension study. Subjects will receive the same study drug (hetrombopag or placebo) as in study HR-TPO-SAA-III, with the same doses and administration schedule or with modifications based on the actual conditions. The primary objective of this extension study is to give the subjects participating in the HR-TPO-SAA-III study the continued access to the study drug (hetrombopag or placebo) after the completion of the HR-TPO-SAA-III study.

Conditions

  • Treatment-naive Severe Aplastic Anemia

Interventions

  • Hetrombopag OlamineDrug

    Hetrombopag Olamine; once daily

  • PlaceboDrug

    Placebo; once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The ratio of subjects with clonal evolution at 6 months and 18 monthsTime frame: 6 months and 18 months
  2. All SIEs, regardless of whether they are related to the investigational productTime frame: 3 years
  3. All SAEs, regardless of whether they are related to the investigational productTime frame: 3 years
  4. All AEs resulting in discontinuation and withdrawal from studyTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.